It is with heartfelt gratitude that the Division of Hematology & Hematologic Malignancies announces the retirement of Dr. Martha Jane Glenn. Dr. Glenn has provided immeasurable service with the Division since 1997. She is a renowned clinician, educator, and mentor who has been a cornerstone of our Division. When Dr. Glenn first arrived at the University of Utah, there was hardly any clinical research in hematologic malignancies and no specialization to speak of. Drawing on her experience at Memorial Sloan Kettering Cancer Center, Dr. Glenn began to modernize the clinical program, focusing on disease focused programs to promote state of the art care and research. Dr. Glenn made an invaluable continuation to the Division’s ascend to become the prime clinical and scientific hematology program in the Mountain West. Dr. Glenn was instrumental in growing our program in lymphoid malignancies from its humble beginning to a group of five highly accomplished physicians who provide expert care to thousands of patients. Today our lymphoma program is one of the most active clinical trial research programs at Huntsman Cancer Institute, and enjoys a national reputation for its clinical excellence and dedication to compassionate care. Dr. Glenn has devoted herself to the educational, research, and clinical missions. She became a member of the Hematology/Oncology Fellowship Committee in 1999 and by 2003 she was appointed Director of the Hematology/Oncology Fellowship Program. She was the Director for 14 years, educating and mentoring more than 50 fellows. Dr. Glenn’s contribution to improving the health of the people in our region is felt at many levels, and not the least through the outstanding mentoring and education provided to our fellows who went on to become highly competent physicians who now practice in our region. In recognition of this work she was one of the original fellows selected into the UUMC Academy of Medical Science Educators in 2013. Dr. Glenn was also appointed as Lymphoma Program Leader for the Huntsman Cancer Institute Hematologic Malignancy Program in 2016. She is a recognized regional expert in lymphoproliferative disorders, and she receives referrals from a six-state region. She is also a member of the National Comprehensive Cancer Network Non-Hodgkin’s Lymphoma panel (NCCN NHL) and is a Huntsman Cancer Institute principal investigator on several lymphoma therapeutic trials. In essence, Dr. Glenn has made outstanding and lasting contributions to the Division and to the wider community. She has created a legacy of clinical expertise, compassionate care, unmatched collegiality, and devotion to better others within the realms of Hematology. Please join with the Division of Hematology & Hematologic Malignancies in expressing sincere appreciation for Dr. Glenn and her invaluable stewardship. She will be greatly missed, and we wish her well in retirement.